News
Business Update: Motif Bio
Jan 05 2021
Reclassified as an AIM Rule 15 cash shell, following completion of restructuring approved by shareholders in November 2019, Motif Bio plc (AIM: MTFB), announces a business update regarding progress towards completing a reverse take-over pursuant to AIM Rule 14 (“RTO”).
The Company is currently advancing the necessary work streams to complete the RTO process with a UK based candidate in the healthcare sector. The Board expects to provide shareholders with a further update during the second half of January.
Following its reclassification as an AIM Rule 15 cash shell in January 2020, the Company is required to make an acquisition which constitutes a RTO by 28 January 2021, failing which the Company's admission to trading on AIM may be cancelled. At this stage, there can be no assurance that the Company will be able to complete this or any other RTO transaction.
The person responsible for the release of this announcement on behalf of Motif Bio is Jonathan Gold, President and Chief Business Officer.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
Digital Edition
ILM 50.3 April 2025
May 2025
Chromatography Articles - Optimising two-step purification: Key considerations for sample pump setups Mass Spectrometry & Spectroscopy Articles - Detecting pharmaceuticals and their transf...
View all digital editions
Events
Apr 27 2025 Portland, OR, USA
Making Pharmaceuticals Exhibition & Conference
Apr 29 2025 Coventry, UK
Apr 30 2025 Peshawar, Pakistan
May 11 2025 Vienna, Austria
May 13 2025 Oklahoma City, OK, USA